Sign In
Buy ETON
$46.42
-2.61 (-5.32%)
At Close: Jul 31, 2026
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
06:50am, Friday, 27'th Jun 2025
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
05:26pm, Friday, 06'th Jun 2025
Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attr
Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why
01:05pm, Monday, 02'nd Jun 2025
Eton Pharmaceuticals (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why
09:50am, Monday, 02'nd Jun 2025
Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
12:42pm, Thursday, 29'th May 2025
The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.'s ETON new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric pat
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
05:28pm, Wednesday, 28'th May 2025
• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd • Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE®
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
02:57am, Wednesday, 21'st May 2025
Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patien
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
04:30pm, Wednesday, 14'th May 2025
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali
Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript
10:40pm, Tuesday, 13'th May 2025
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
06:20pm, Tuesday, 13'th May 2025
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.03 per share a year ago.
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
04:01pm, Tuesday, 13'th May 2025
DEER PARK, Ill., May 13, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
04:30pm, Thursday, 01'st May 2025
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
11:07am, Thursday, 01'st May 2025
Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
06:50am, Monday, 28'th Apr 2025
- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch –
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
07:00am, Tuesday, 01'st Apr 2025
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercia
